ATNM News and Press, Actinium Pharmaceuticals Inc. From 01/02/24

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation &...

2023-12-26 13:10:19 ET More on Actinium Pharmaceuticals Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy Seeking Alpha’s Quant Rating on Actinium Pharmaceuticals Historical earnings data for Actinium Pharmaceuticals Financial ...

2023-12-26 08:22:28 ET Gainers: RayzeBio ( RYZB ) +100% on being acquired by Bristol Myers Squibb . Gracell Biotechnologies ( GRCL ) +60% to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases . IMAC Holdings ( BA...

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation PR Newswire Relapsed or refractory AML patients with TP53 mutation known to have dismal outc...

Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia PR Newswire Oral presentation highlighted Iomab-B improves overall survival in patients with TP53 mutation with ac...

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Acti...

2023-11-03 18:08:52 ET Summary Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. The main pipeline update is the presentation of findings in patients with TP53 mutation, showing impro...

Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023 PR Newswire NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announc...

Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial PR Newswire -   ...

Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy PR Newswire - Ongoing clinical trial is the first ever to combine targeted radiotherapy conditi...